Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocutears Aloe+ for post-cataract surgery dry eye disease
ChiCTR2600130064Phase 4Not yet recruiting
- Sponsor
- Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Ocutears Aloe+ in dry eye syndrome (DED), sponsored by Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital. Primary endpoint: Corneal fluorescein staining score (modified Oxford scale) at week 3. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Ocutears Aloe+
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2600130064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130064.